Abstract 82P
Background
Recent studies revealed contrasting prognostic roles of body-mass index (BMI) and tumor location in colorectal cancer (CRC). Given that right-sided and left-sided CRC may exhibit inverse impact on outcome and body weight, the present study is to examine whether the prognostic value of BMI and tumor location could be stratified reciprocally.
Methods
This prospective, observational study recruited 4,086 patients with diagnosed stage III CRC from 5 independent clinical centers in China. verall survival (OS) and disease-specific survival (DSS) was included as the clinical endpoints. The association of patients’ outcome with BMI and tumor location was evaluated hierarchically by Kaplan-Meier and Cox proportional-hazards model.
Results
Although BMI was not associated with outcome within total patients, this association was significantly modified by tumor location. Among left-sided tumors, obesity and overweight was significantly associated with adverse OS and DSS. In contrast, among right-sided tumors, overweight was significantly associated with more favorable OS and DSS compared with normal-weight group. The association of survival with tumor location did not reach statistical significance either. However, hierarchical analysis by BMI revealed that left-sided tumors were associated with more favorable outcome in normal-weight group, while no statistically significant difference in overweight or obese group.
Conclusions
BMI and tumor location may have opposing prognostic impact on CRC, stratified by each other, after adjusting for known prognostic factors. These findings are the first to show the interactive prognostic impact of BMI and tumor location, which could be relevant to stratification of patients' management.
Clinical trial identification
NCT02215642.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract